WallStreetZenWallStreetZen

NASDAQ: MEDS
Trxade Health Inc Stock

$9.10-0.10 (-1.09%)
Updated Jun 21, 2024
MEDS Price
$9.10
Fair Value Price
-$9.42
Market Cap
$12.80M
52 Week Low
$3.69
52 Week High
$44.56
P/E
-0.39x
P/B
23.6x
P/S
0.48x
PEG
N/A
Dividend Yield
0%
Revenue
$8.27M
Earnings
-$17.84M
Gross Margin
31.4%
Operating Margin
-201.22%
Profit Margin
-215.7%
Debt to Equity
22.11
Operating Cash Flow
-$2M
Beta
0.54
Next Earnings
Aug 16, 2024
Ex-Dividend
N/A
Next Dividend
N/A

MEDS Overview

TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.

Zen Score

Industry Average (17)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MEDS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MEDS ($9.10) is overvalued by 196.56% relative to our estimate of its Fair Value price of -$9.42 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MEDS ($9.10) is not significantly undervalued (196.56%) relative to our estimate of its Fair Value price of -$9.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MEDS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MEDS due diligence checks available for Premium users.

Be the first to know about important MEDS news, forecast changes, insider trades & much more!

MEDS News

Valuation

MEDS fair value

Fair Value of MEDS stock based on Discounted Cash Flow (DCF)
Price
$9.10
Fair Value
-$9.42
Undervalued by
196.56%
MEDS ($9.10) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MEDS ($9.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MEDS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MEDS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.39x
Industry
-2.36x
Market
30.75x

MEDS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
23.6x
Industry
1.04x
MEDS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MEDS's financial health

Profit margin

Revenue
$2.4M
Net Income
-$11.7M
Profit Margin
-498%
MEDS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MEDS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$12.5M
Liabilities
$12.0M
Debt to equity
22.11
MEDS's short-term liabilities ($11.56M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MEDS's short-term assets ($2.75M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MEDS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MEDS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$867.5k
Investing
-$350.0k
Financing
$1.3M
MEDS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MEDS vs Pharmaceutical Retailer Stocks

TickerMarket Cap1d %P/EP/B
MEDS$12.80M-1.09%-0.39x23.60x
BIMI$14.83M-2.29%-0.49x1.70x
LFLY$5.68M+2.35%-0.76x-0.40x
SSY$4.18M-20.93%-0.57x0.36x
CJJD$3.89M-0.39%-0.06x0.21x

Trxade Health Stock FAQ

What is Trxade Health's quote symbol?

(NASDAQ: MEDS) Trxade Health trades on the NASDAQ under the ticker symbol MEDS. Trxade Health stock quotes can also be displayed as NASDAQ: MEDS.

If you're new to stock investing, here's how to buy Trxade Health stock.

What is the 52 week high and low for Trxade Health (NASDAQ: MEDS)?

(NASDAQ: MEDS) Trxade Health's 52-week high was $44.56, and its 52-week low was $3.69. It is currently -79.58% from its 52-week high and 146.61% from its 52-week low.

How much is Trxade Health stock worth today?

(NASDAQ: MEDS) Trxade Health currently has 1,406,348 outstanding shares. With Trxade Health stock trading at $9.10 per share, the total value of Trxade Health stock (market capitalization) is $12.80M.

Trxade Health stock was originally listed at a price of $97.50 in Feb 13, 2020. If you had invested in Trxade Health stock at $97.50, your return over the last 4 years would have been -90.67%, for an annualized return of -44.73% (not including any dividends or dividend reinvestments).

How much is Trxade Health's stock price per share?

(NASDAQ: MEDS) Trxade Health stock price per share is $9.10 today (as of Jun 21, 2024).

What is Trxade Health's Market Cap?

(NASDAQ: MEDS) Trxade Health's market cap is $12.80M, as of Jun 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Trxade Health's market cap is calculated by multiplying MEDS's current stock price of $9.10 by MEDS's total outstanding shares of 1,406,348.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.